查看2017.HSA.doxorubicin.AC.vs.ADTIC的源代码
←
2017.HSA.doxorubicin.AC.vs.ADTIC
跳转到:
导航
,
搜索
因为以下原因,你没有权限编辑本页:
您刚才请求的操作只有这个用户组中的用户才能使用:
用户
您可以查看并复制此页面的源代码:
== 摘要 == 犬血管肉瘤 (HSA) 是一种血管内皮起源的肿瘤,具有侵袭性生物学行为,在诊断后 12 个月内存活的狗不到 10%。首选的治疗包括手术,然后以阿霉素为基础的辅助化疗。我们前瞻性地比较了阿霉素和达卡巴嗪(ADTIC)辅助治疗与传统的多柔比星和环磷酰胺(AC)治疗,旨在确定安全性并评估该方案是否能延长生存期和转移时间(TTM)。招募了 27 只狗;分期检查后,18 例接受 AC 治疗,9 例接受 ADTIC 治疗。与接受 AC 治疗的狗相比,接受 ADTIC 治疗的狗的中位 TTM 和生存时间更长(分别为 >550 天 对 112 天,>550 天 P=0.021 对 142 天 P=0.011)。两种方案的耐受性都很好,不需要减少剂量或增加治疗间隔。由多柔比星和达卡巴嗪联合组成的方案在患有 HSA 的狗中是安全的,并延长了 TTM 和生存时间。 Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112 days, P = 0.021 and >550 versus 142 days, P = 0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time. <br>
返回到
2017.HSA.doxorubicin.AC.vs.ADTIC
。
个人工具
登录
名字空间
页面
讨论
变换
查看
阅读
查看源代码
查看历史
操作
搜索
导航
首页
社区专页
新闻动态
最近更改
随机页面
帮助
工具箱
链入页面
相关更改
特殊页面